341 related articles for article (PubMed ID: 23878310)
1. Biosimilars in rheumatology: perspective and concerns.
Scheinberg MA; Azevedo VF
Rheumatology (Oxford); 2014 Mar; 53(3):389-90. PubMed ID: 23878310
[No Abstract] [Full Text] [Related]
2. Update on biosimilars in rheumatology.
Rischin A; Östör AJ
Inflammopharmacology; 2017 Apr; 25(2):177-184. PubMed ID: 28265837
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars: how similar?
Strand V; Cronstein B
Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
[TBL] [Abstract][Full Text] [Related]
4. The changing landscape of biosimilars in rheumatology.
Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR
Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144
[TBL] [Abstract][Full Text] [Related]
5. PANLAR consensus statement on biosimilars.
Kowalski SC; Benavides JA; Roa PAB; Galarza-Maldonado C; Caballero-Uribe CV; Soriano ER; Pineda C; Azevedo VF; Avila-Pedretti G; Babini AM; Cachafeiro-Vilar A; Cifuentes-Alvarado M; Cohen SB; Díaz PE; Soto LD; Encalada C; Garro B; Sariego IAG; Guibert-Toledano M; Rodriguez VJK; Lopez MEL; Ortega AP; Russell AS; Santos-Moreno P; Terán IS; Vargas A; Vásquez G; Xavier RM; Firedman DXX; Mysler E; Kay J
Clin Rheumatol; 2019 May; 38(5):1485-1496. PubMed ID: 30915652
[TBL] [Abstract][Full Text] [Related]
6. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE
J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414
[TBL] [Abstract][Full Text] [Related]
7. [Biosimilars].
Burmester GR; Müller-Ladner U
Z Rheumatol; 2015 Oct; 74(8):670-1. PubMed ID: 26450433
[No Abstract] [Full Text] [Related]
8. [Patient safety first. position paper of the German Rheumatism -- Ligazur introduction of biosimilars].
Z Rheumatol; 2014 Sep; 73(7):676. PubMed ID: 25320752
[No Abstract] [Full Text] [Related]
9. Biosimilars in rheumatology: understanding the rigor of their development.
Goel N; Chance K
Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
[TBL] [Abstract][Full Text] [Related]
10. Use of Biologics and Biosimilars in Rheumatology.
Sharma SK
J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745
[TBL] [Abstract][Full Text] [Related]
11. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
Schulze-Koops H; Skapenko A
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
Espinosa Morales R; Díaz Borjón A; Barile Fabris LA; Esquivel Valerio JA; Medrano Ramírez G; Arce Salinas CA; Barreira Mercado ER; Cardiel Ríos MH; Díaz Jouanen E; Flores Murrieta FJ; Fraga Mouret A; Garza Elizondo MA; Luján Estrada M; Muñoz Barradas FJ; Talavera Piña JO; Vera Lastra OL;
Reumatol Clin; 2013; 9(2):113-6. PubMed ID: 23395225
[TBL] [Abstract][Full Text] [Related]
14. Potential for biosimilars in rheumatology in Africa.
Abu-Zaid MH; Adebajo A; El Miedany Y
Ann Rheum Dis; 2023 Dec; 82(12):1508-1510. PubMed ID: 37468221
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars in rheumatology: the wind of change.
Schneider CK
Ann Rheum Dis; 2013 Mar; 72(3):315-8. PubMed ID: 23390018
[No Abstract] [Full Text] [Related]
16. Biosimilars in rheumatology.
Araújo FC; Gonçalves J; Fonseca JE
Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
[TBL] [Abstract][Full Text] [Related]
17. [Biosimilars in rheumatology. Development and results of clinical trials].
Alten R
Z Rheumatol; 2015 Oct; 74(8):682-8. PubMed ID: 26347121
[TBL] [Abstract][Full Text] [Related]
18. Comment on: The Portuguese Society of Rheumatology position paper on the use of biosimilars.
Müller-Ladner U
Acta Reumatol Port; 2014; 39(1):7-8. PubMed ID: 24811455
[No Abstract] [Full Text] [Related]
19. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in rheumatology: current perspectives and lessons learnt.
Dörner T; Kay J
Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]